Advertisement
Advertisement
U.S. markets close in 6 hours 2 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.5800+0.0017 (+0.29%)
As of 09:57AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.5783
Open0.5920
Bid0.5856 x 800
Ask0.5900 x 900
Day's Range0.5701 - 0.5999
52 Week Range0.4100 - 4.9100
Volume252,377
Avg. Volume702,535
Market Cap73.025M
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-1.2090
Earnings DateMay 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ORTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Orchard Therapeutics plc
    Daily – Vickers Top Buyers & Sellers for 09/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • GlobeNewswire

    Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress

    Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LO

  • GlobeNewswire

    Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond

    BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C. Featured presentations include updated results on the OTL-203 clinical program for mucopolysaccharidosis type I Hurler syndrome (MPS-IH), as well as several accepted abstracts highlighting

  • GlobeNewswire

    Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results

    BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 2022 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing +1 (

Advertisement
Advertisement